Download List of Publications: As a Corresponding/Senior Author 1. Tumor

List of Publications:
As a Corresponding/Senior Author
1. Tumor-derived vascular pericytes anergize T helper cells (2013) Bose A*, Barik S,
Banerjee S, Ghosh T, Mallick A, Bhattacharya Majumdar S, Goswami KK, Bhuniya A,
Banerjee S, Baral R, Storkus WJ, Dasgupta PS, Majumdar S. J Immunol, 191, 971-981.
*Corresponding Author.
Impact Factor: 5.59; Citation Index: 9. Cited as a featured article in www.MDLinx.com; 1st
among Top 20 articles in the Domain of Article 23785117, Since 2013
2. Neem leaf glycoprotein activates CD8+ T cells to promote therapeutic anti-tumor immunity
inhibiting the growth of mouse sarcoma (2013) Mallick A, Barik S, Goswami KK, Banerjee
S, Ghosh S, Sarkar K, Bose A*, Baral R*. PLoS One, 8, e47434. *Corresponding
Authors.
Impact Factor: 4.09; Citation Index: 17
3. TLR signaling mediated differential histone modification at IL-10 and IL-12 promoter
region leads to functional impairments in tumor associated macrophages(2011).
Banerjee S, Halder K, Bose A*, Bhattacharya P, Gupta G, Mahapatra SK, Das S,
Chowdhury S, Majumdar SB, Majumdar S*. Carcinogenesis, 32, 1789-97. *Senior
Authors.
Impact Factor: 5.63; Citation Index: 16
4. Neem leaf glycoprotein prophylaxis transduces immune dependent stop signal for tumor
angiogenic switch within tumor microenvironment (2014) Banerjee S, Ghosh T, Barik S,
Das A, Ghosh S, Bose A*, Baral R*, PLoS One, 9, e110040. *Senior Authors.
Impact Factor: 4.09; Citation Index: 1
5. Neem leaf glycoprotein promotes dual generation of central and effector memory CD8+ T
cells against sarcoma antigen vaccine to induce protective anti-tumor immunity (2015).
Ghosh S, Sarkar M, Ghosh T, Guha I, Bhuniya A, Saha A, Dasgupta S, Barik S, Bose A*,
Baral R*. Mol Immunol (in press)*Both authors contributed equally as senior author.
Impact Factor: 2.97; Citation Index: Yet to cite
As a Corresponding/Senior Author (Communicated)
1. Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking
cysteine export from dendritic cells (2015). Ghosh T, Barik S, Bhuniya A, Dhar J, Ghosh
S, Sarkar M, Guha I, Sarkar K, Chakraborti P, Saha B, Storkus WJ, Baral R, Bose A*.
Communicated to Cancer Res. *Corresponding Author.
2. Immunoregulatory role of non-hematopoetic stromal cells residing at tumor
microenvironment (2015). Bose A*, Ghosh T, Baral R. (invited review article)
Communicated to Oncoimmunology. *Corresponding Author.
3. Absence of CD4+ T cell help generates corrupt CD8+ effector T cells in sarcoma bearing
Swiss mice treated with NLGP-vaccine (2015). Ghosh S, Sarkar M, Ghosh T, Guha I,
Bhuniya A, Biswas J, Mallick A, Bose A*, Baral R*. Communicated to PLoS One. *Both
authors contributed equally as senior author.
4. Neem leaf glycoprotein regulates expression and function of tumor associated M2
macrophages in immunosuppressed hypoxic tumor core: Critical role of IL-10/STAT3
signalling (2015). Goswami KK, Barik S, Ghosh T, Sarkar M, Banerjee S, Roy S, Bose
A*, Dasgupta PS, Baral R*. Communicated to J Leukocyte Biol. *Both authors contributed
equally as senior author.
As a First Author
1. Tumor-derived vascular pericytes anergize T helper cells (2013). Bose A*, Barik S,
Banerjee S, Ghosh T, Mallick A, Bhattacharya Majumdar S, Goswami KK, Bhuniya A,
Banerjee S, Baral R, Storkus WJ, Dasgupta PS, Majumdar S. J Immunol, 191, 971-981.
*Corresponding Author.
Impact Factor: 5.59; Citation Index: 9
2. Dasatinib promotes an expanded and therapeutically-superior T cell repertoire in
response to vaccination against melanoma (2014). Low DB*, Bose A*, Taylor JL,
Tawabi H, Lin Y, Kirkwood JM, Storkus WJ. Oncoimmnunology, 3, e27589. *both
authors contributed equally.
Impact Factor: 6.28; Citation Index: 5
3. Vaccines targeting tumor-associated stromal antigens are protective/therapeutic in HLAA2 transgenic mice (2012). Bose A*, Zhao X*, Komita H, Taylor JL, Chi N, Lowe D,
Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. J Immunol, 188, 17821788. *both authors contributed equally.
Impact Factor: 5.52; Citation Index: 16
4. Combined vaccine + axitinib therapy yields superior anti-tumor efficacy in murine
melanoma model (2012). Bose A, Lowe LB, Storkus WJ. Melanoma Res, 22, 236-243.
Impact Factor: 2.52; Citation Index: 23
5. Intratumoral IL-12 gene therapy results in the cross priming of Tc1 cells reactive against
tumor associated stromal antigens (2011). Bose A*, Zhao X*, Komita H, Taylor JL,
Kawabe M, Chi N, Spokas L, Lowe D, Doldbach C, Alber S, Watkins SC, Butterfield LH,
Kalinski P, Kirkwood JM, Storkus WJ. Mol Ther, 19, 805-814. *both authors contributed
equally.
Impact Factor: 7.04; Citation Index: 27
6. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Finke JH, Storkus
WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity
in concert with specific vaccination. Int J Cancer, 129, 2158-70, 2011.
Impact Factor: 6.20; Citation Index: 70
7. Neem leaf glycoprotein induces perforin mediated tumor cell killing by T and NK cells
through differential regulation of IFNα signaling (2009) Bose A, Chakraborty K, Sarkar
K, Chakraborty T, Goswami S, Pal S and Baral R., J Immunother, 32, 42-53.
Impact Factor: 4.84; Citation Index: 27
8. Neem leaf glycoprotein directs T-bet associated type 1 immune commitment (2009)
Bose A, Chakraborty K, Sarkar K, Goswami S, Haque E, Chakraborty T, Ghosh D, Roy
S, Laskar S and Baral RN, Human Immunol, 70, 6-15.
Impact Factor: 3.06; Citation Index: 23
9. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral
blood mononuclear cells from head and neck squamous cell carcinoma patients (2008)
Bose A, Chakraborty T, Chakraborty K, Pal S and Baral R. Cancer Immunity, 8, 10.
Citation Index: 57
10. NK cellular cytotoxicity of tumor cells initiated by neem leaf preparation is associated
with CD40-CD40L mediated endogenous production of IL-12 (2007). Bose A and Baral
RN, Human Immunol, 68, 823-831.
Impact Factor: 3.06; Citation Index: 36
11. Neem leaf preparation induces apoptosis of tumor cells by releasing cytotoxic cytokines
from human peripheral blood mononuclear cells (2007) Bose A, Haque E and Baral
RN,. Phytother Res, 21, 914-920.
Impact Factor: 0.88; Citation Index: 34
12. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell
mediated tumor cell cytotoxicity (2007). Bose A and Baral RN, Immunol Lett, 108, 6877.
Impact Factor: 3.06; Citation Index: 16
13. Interferonalpha2b augments suppressed immune functions in tobacco related head and
neck squamous cell carcinoma patients by modulating cytokine signaling (2006), Bose
A, Ghosh D, Pal S, Mukherjee K, Biswas J, Baral RN, Oral Oncol, 42, 161-171.
Impact Factor: 3.93; Citation Index: 22
As an Associated Author
1. Mycobacterium indicus pranii (Mw) inhibits invasion by reducing matrix
metalloproteinase (MMP-9) via AKT/ERK-1/2 and PKCa signaling: A potential
candidate in melanoma cancer therapy (2015) Halder K, Banerjee S, Ghosh S, Bose
A, Das S, Chowdhury BP, Majumdar S. Cancer Bio Ther, Sep 21, Epub ahead of
print.
Impact Factor: 3.07; Citation Index: Yet to cite
2. Therapeutic anti-NLGP monoclonal antibody for carcinoembryonic antigen expressing
tumors is nontoxic to Swiss and BALB/c mice (2015) Das A, Mondal B, Bose A,
Biswas J, Baral R, Pal S, Int Immunopharmacol, 28, 785-793.
Impact Factor: 2.42; Citation Index: Yet to cite
3. The combination of a novel immunomodulator with a Treg suppressing antibody
(DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor
associated macrophages in situ (2015) Banerjee S, Halder K, Ghosh S, Bose A,
Majumdar S, Oncoimmunology, 4, e995559.
Impact Factor: 6.28; Citation Index: 2
4. Chemical investigation of neem leaf glycoprotein used as immunoprophylactic agent
for tumor growth restriction (2015) Kundu P, Bark S, Sarkar K, Bose A, Baral R,
Laskar S, Int J Pharm Pharmaceu Sc, 7, 195-199.
Impact Factor: 0.91; Citation Index: Yet to cite
5. Carcinoembryonic antigen expressing murine carcinoma growth is restricted by
antibody against neem leaf glycoprotein (2014) Das A, Barik S, Bose A, Roy S,
Biswas J, Baral R, Pal S, Immunology Letters. 162, 132-139.
Impact Factor: 2.37; Citation Index: 1
6. A monoclonal antibody against neem leaf glycoprotein recognizes carcinoembryonic
antigen (CEA) and restricts CEA expressing tumor growth (2014) Das A, Barik S,
Banerjee S, Bose A, Sarkar K, Biswas J, Baral R, Pal S, J Immunother, 37, 394406.
Impact Factor: 3.46; Citation Index: 2
7. Immunotherapeutic targeting of established sarcoma in Swiss mice by tumor derived
antigen pulsed neem leaf glycoprotein matured dendritic cells is CD8+ T cell
dependent (2014) Mallick A, Barik S, Ghosh S, Roy S, Sarkar K, Bose A, Baral R,
Immunotherapy, 6, 821-831.
Impact Factor: 2.39; Citation Index: Yet to cite
8. Targeting STAT3 phosphorylation by neem leaf glycoprotein prevents immune
evasion exerted by supraglottic laryngeal tumor induced M2 macrophages (2014)
Goswami KK, Barik S, Sarkar M, Bhowmick A, Biswas J, Bose A, Baral R, Mol
Immunol, 59, 119-27.
Impact Factor: 2.65; Citation Index: 11
9. Overexpressed PKC delta downregulates the expression of PKC alpha in B16F10
melanoma: Induction of apoptosis by PKC delta via ceramide generation (2014)
Halder K, Banerjee S, Bose A, Majumder S, Majumdar S. PLoS One, 14, e91656.
Impact Factor: 4.09; Citation Index: 5
10. Neem leaf glycoprotein optimizes effector and regulatory functions within tumor
microenvironment to intervene therapeutically the growth of B16 melanoma in
C57BL/6 mice (2015) Barik S, Banerjee S, Sarkar M, Bhuniya A, Roy S, Bose A,
Baral R. Trials in Vaccinology, 4, e80-e87.
Citation Index: 2
11. Supraglottic laryngeal tumor microenvironmental factors facilitate STAT3 dependent
pro-tumorigenic switch in tumor associated macrophages to render utmost immune
evasion (2013) Goswami KK, Barik S, Banerjee S, Bhowmick AK, Biswas J, Bose A,
Baral R. Immunol Lett, 156, 7-17.
Impact Factor: 2.24; Citation Index: 2
12. Normalization of tumor microenvironment by neem leaf glycoprotein potentiates
effector T cell functions and therapeutically intervenes in the growth of mouse
sarcoma (2013) Barik S, Banerjee S, Mallick A, Goswami KK, Roy S, Bose A, Baral
R. PLoS One, 8, e66501.
Impact Factor: 4.09; Citation Index: 8
13. Neem leaf glycoprotein is superior than Cisplatin and Sunitinib malate in restricting
melanoma growth by normalization of tumor microenvironment (2013) Barik S,
Bhuniya A, Banerjee S, Das A, Sarkar M, Paul T, Ghosh T, Ghosh S, Roy S, Pal S,
Bose A, Baral R. Int Immunopharmacol, 17, 42-49.
Impact Factor: 2.42; Citation Index: 3
14. Neem leaf glycoprotein overcomes indoleamine 2, 3 dioxygenase mediated
tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical
cancer stage IIIB patients (2013) Roy S, Barik S, Banerjee S, Pal S, Basu PS,
Biswas J, Goswami S, Chakraborty T, Bose A, Baral R. Human Immunol, 74, 10151023.
Impact Factor: 2.30; Citation Index: 4
15. Neem leaf glycoprotein is nontoxic to physiological functions of Swiss mice and
Sprague Dawley rats: Histological, biochemical and immunological perspectives
(2013) Mallick A, Ghosh S, Banerjee S, Majumder S, Das A, Mondal B, Barik S,
Goswami KK, Pal S, Laskar S, Sarkar K, Bose A, Baral R, Int Immunopharmacol,
15, 73-83.
Impact Factor: 2.38; Citation Index: 10
16. Neem leaf glycoprotein suppresses regulatory T cell mediated suppression of
monocyte/macrophage functions (2012) Chakraborty T, Bose A, Goswami KK,
Goswami S, Chakraborty K, Baral R, Int Immunopharmacol, 12, 326-333.
Impact Factor: 2.47; Citation Index: 6
17. IFNα2b Augments Immune responses of Cisplatin+5-Fluorouracil treated tongue
squamous cell carcinoma patients (2012) Mukherjee KK, Bose A, Ghosh D, Sarkar
K, Goswami S, Pal S, Biswas J, Baral R. Ind J Med Res, 136, 54-59.
Impact Factor: 1.50; Citation Index: 3
18. Dysregulated CC receptor-ligand signaling for monocyte chemotaxis in oral
squamous cell carcinoma patients is partially rectified by interferon alpha 2b (2011)
Chakraborty K, Bose A, Mukherjee KK, Goswami KK, Ghosh D, Goswami S,
Chakraborty T, Sarkar K, Pal S, Bhowmick A, Biswas J, Baral R, Human Immunol.,
73, 38-47.
Impact Factor: 2.87; Citation Index: 4
19. Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ regulatory T cells to restrict
murine tumor growth (2011) Chakraborty T, Bose A, Barik S, Goswami K, Banerjee
S, Goswami S, Ghosh D, Roy S, Chakraborty K, Sarkar K and Baral R,
Immunotherapy, 3, 949-969.
Impact Factor: 1.85; Citation index: 12
20. Defective dendritic cell generation from monocytes is a potential reason for poor
therapeutic efficacy of IFNa2b in cervical cancer (2011) Roy S, Goswami S, Bose A,
Sarkar K, Chakraborty K, Chakraborty T, Pal S, Haldar A, Basu P, Biswas J, Baral
R, Translational Res, 158, 200-213.
Impact Factor: 2.90; Citation index: 4
21. IL-32 gene therapy potentiates anti-tumor immunity in murine tumor model.Qu Y,
Taylor JL, Bose A, Storkus WJ (2011) Cancer Gene Ther, 18, 663-673.
Impact Factor: 2.94; Citation Index: 7
22. Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and
associated T cell efficacy in stage IIIB cervical cancer patients (2011) Roy S,
Goswami S, Bose A, Chakraborty T, Chakraborty K, Pal S, Haldar A, Basu PS,
Biswas J, Baral R., Clin Vaccine Immunol, 18, 571-579.
Impact Factor: 2.47; Citation index: 11
23. Restoration of dysregulated CC chemokine signaling for monocyte/macrophage
chemotaxis in head and neck squamous cell carcinoma patients by neem leaf
glycoprotein maximizes tumor cell cytotoxicity (2010) Chakraborty K, Bose A,
Chakraborty T, Sarkar K, Goswami S, Pal S, Baral R. Cell Mol Immunol (Nature
Publishing Group), 7, 396-408.
Impact Factor: 2.77; Citation index: 18
24. Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic
cells to T and B cells for induction of anti-tumor immunity by allowing generation of
immune effector/memory response (2010) Sarkar K, Goswami S, Roy S, Mallick A,
Chakraborty K, Bose A, Baral R. Int Immunopharmacol, 10, 865-874.
Impact Factor: 2.21; Citation Index: 21
25. Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes antitumor T cell functions (2010) Goswami S, Bose A, Sarkar K, Roy S, Chakraborty T,
Sanyal U, Baral R. Vaccine, 28, 1241-1252.
Impact Factor: 3.30; Citation Index: 28
26. Neem (Azadirachta indica) leaf preparation prevents leukocyte apoptosis mediated
by cisplatin plus 5-fluorouracil treatment in Swiss mice (2009) Ghosh D, Bose A,
Haque E, Baral R. Chemotherapy, 55, 137-144.
Impact Factor: 1.52; Citation Index: 12
27. Association of early phase of colorectal carcinogenesis with STAT3 activation and its
relevance in apoptosis regulation (2009) Baral R, Bose A, Ray C, Paul S, Pal S,
Haque E, Mishra B, Nagpal JK, Das BR. Exp Mol Pathol, 87, 36-41.
Impact Factor: 1.93; Citation Index: 9
28. Induction of type1 cytokine during neem leaf glycoprotein assisted carcinoembryonic
antigen vaccination is associated with nitric oxide production (2009) Sarkar K, Bose
A, Haque E, Chakraborty K, Chakraborty T, Goswami S, Ghosh D, and Baral RN,.
Int Immunopharmacol, 9, 753-760.
Impact Factor: 2.21; Citation Index: 12
29. Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific
antitumor immune responses utilizing macrophage mediated antigen presentation
(2008) Sarkar K, Bose A, Chakraborty K, Haque E, Ghosh D, Goswami S,
Chakraborty T, Laskar S and Baral RN, Vaccine, 26, 4352-4362.
Impact Factor: 3.30; Citation Index: 28
30. Interferon alpha 2b restores the impaired chemotactic activity of peripheral blood
mononuclear cells from head and neck squamous cell carcinoma patients by
modulation CXCreceptor ligand interaction (2008) Chakraborty K, Bose A, Pal S,
Chattopadhyay U and Baral RN, J Interferon Cytokine Res, 28, 19-32.
Impact Factor: 2.67; Citation Index: 6
31. Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood
mononuclear cells from head and neck squamous cell carcinoma patients by
maintaining CXCR3/CXCL10 balance (2008) Chakraborty K, Bose A, Pal S, Sarkar
K, Goswami S, Chattopadhyay U, Baral RN, Int Immunopharmacol, 8, 330-340.
Impact Factor: 2.67; Citation Index: 31
32. Antibody response against neem leaf preparation recognizes carcinoembryonic
antigen (2007) Sarkar K, Bose A, Laskar S, Chaudhuri SK, Dey S, Roychoudhuri
PK, Baral RN, Int Immunopharmacol, 7, 306-312.
Impact Factor: 3.30; Citation Index: 23
33. Pretreatment with neem (Azadirachta indica) leaf preparation in Swiss mice
diminishes leukopenia and enhances anti-tumor activity of cyclophosphamide (2006)
Ghosh D, Bose A, Haque E, Baral RN, Phytother Res, 20, 814-818,.
Impact Factor: 0.88; Citation Index: 23
Cumulative Impact Factor: 156.12; Cumulative Citation Index: 707 (till December
22, 2015)
Patents:
1. Process for isolating glycoprotein(s) from neem leaf, which has immunomodulatory and
cancer preventive functions (2012) Baral RN, Laskar S, Bose A, Sarkar K, (Indian
Patent). Patent No. 259434.
2. Vaccines for the promotion of immune response against tumor-associated stromal
antigens (2011) Storkus WJ, Bose A, Taylor JL, Zhao X, Lowe DB. (Ref No. 02386).
Book Chapters:
1. Neem leaf glycoprotein as a new vaccine adjuvant for cancer immunotherapy. In:
“Comprehensive Bioactive Natural Products; Immune-modulation & Vaccine Adjuvants”
(Ed. V. K. Gupta), Baral RN, Sarkar K, Mandal-Ghosh I, Bose A, Vol 5, Chap 2, Studium
Press LLC, USA, 2010, pp. 21-45.
2. Cancer Immunoediting: Prefessional Editorship by Neem leaf glycoprotein. In:
“Treatments of Advanced Stage Cancers: current status and emerging frontiers” (Ed. G.
P. Talwar & O. P. Sood), Bose A, Chakraborty K, Sarkar K, Goswami S, Chakraborty
T,Haque E, Ghosh D, Mandal-Ghosh I, Pal S, Laskar S, Chattopadhyay U and Baral
RN. Narosa Publishing House Pvt. Ltd, India, 2009, pp 148-152.
3. Suppression of Suppressors: Neem leaf glycoprotein Guided Crosstalk Between
Regulatory T cells and T cells/NK Cells/ Macrophages in Cancer. In: “Treatments of
Advanced Stage Cancers: current status and emerging frontiers” (Ed. G. P. Talwar & O.
P. Sood), Chakraborty T, Bose A, Chakraborty K, Sarkar K, Goswami S, ,Haque E,
Ghosh D, Mandal-Ghosh I, Pal S, Laskar S and Baral RN. Narosa Publishing House
Pvt. Ltd, India, 2009, pp 153-157.
4. Immunotherapeutic targeting of multiple dysregulated immune functions in cancer by
neem leaf glycoprotein. In: “Medicinal Plants: Phytochemistry, Pharmacology and
Therapeutics.” (Ed. V. K. Gupta), Bose A, Goswami S, Roy S, Chakraborty K,
Chakraborty T, Sarkar K and Baral R. Daya Publishing House, New Delhi, 2012, pp. 4178.
5. Tumor and its environment: Effort by neem leaf glycoprotein to keep it green. In:
“Bioactive Phytochemicals, perspectives for Modern Medicine” (Ed. V. K. Gupta) Vol 2,
Barik S, Goswami KK, Mallick A, Banerjee S, Bose A, Baral R. Daya Publishing House
(Astral Int. Pvt. Lyd.), New Delhi, 2014, 51-82.
Manuscripts communicated/under preparation:
1. An unusual non-professional immune cell-like behavior of tumor-associated perivascular
cells. (opinion article) Bose A*, Baral R, Majumdar S, Storkus WJ. Manuscript under
preparation. *Corresponding Author
2. Immunomodulator neem leaf glycoprotein has no interference on male and female
reproductive functions of Swiss mice. Ghosh T, Barik S, Paul M, Mandal B, Das A, Bose
A, Baral R. Communicated to Ind J Exptl Biol.